Viridian Therapeutics price target raised to $36 from $35 at Oppenheimer

Oppenheimer raised the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $35 and keeps an Outperform rating on the shares following data update and decision to take VRDN-003 forward as the company’s subQ for TED pivotal development. Although IV VRDN-001 stands as the company’s first-to-market opportunity that Oppenheimer expects to gain modest share against Amgen’s (AMGN) Tepezza through a shorter dosing regimen and potentially favorable safety, the firm views ‘003 – being developed for self-administration by autoinjector pen as infrequently as once every two months – as Viridian’s key value driver and market winner.